Abstract
The Renal Insufficiency and Anticancer Medications (IRMA) study is a French national, observational study which demonstrated the high prevalence of abnormal renal function in a population of 4,684 solid tumour patients. Among them, 50–60% had decreased renal function defined as CrCl below 90 and 80% were treated with anticancer drugs that either necessitated dosage adjustment in case of RI or were potentially nephrotoxic drugs. Since patients and drugs used differ depending on the type of tumour, the IRMA Study Group started analyses in different subgroups of patients. In the 1898 IRMA patients with breast cancer, the prevalence of RI was still very high in spite of a normal serum creatinine in almost all cases. Some anticancer drugs, as in particular some bisphosphonates, capecitabine and platinum salts, may be nephrotoxic and/or need dosage adjustment. However other important drugs in breast cancer do not require dose reduction, and do not present with potential nephrotoxicity (anthracyclines, taxanes, trastuzumab). Both issues seem to be slightly but significantly more important in patients with bone metastases as compared to patients with a non-metastatic disease.
Similar content being viewed by others
References
Matas AJ, Simmons RL, Kjellstrand CM, Buselmeier TJ, Najarian JS (1975) Increased incidence of malignancy during chronic renal failure. Lancet 1:883–886. doi:10.1016/S0140-6736(75)91684-0
Sutherland GA, Glass J, Gabriel R (1977) Increased incidence of malignancy in chronic renal failure. Nephron 18:182–184. doi:10.1159/000130762
Cengiz K (2002) Increased incidence of neoplasia in chronic renal failure (20-year experience). Int Urol Nephrol 33:121–126. doi:10.1023/A:1014489911153
Jones CA, McQuillan GM, Kusek JW et al (1998) Serum creatinine levels in the US population: third national health and nutrition examination survey. Am J Kidney Dis 32:992–999. doi:10.1016/S0272-6386(98)70074-5
Launay-Vacher V, Oudard S, Janus N, Gligorov J, Pourrat X, Rixe O, Renal Insufficiency and Cancer Medications (IRMA) Study Group et al (2007) Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer 110(6):1376–1384. doi:10.1002/cncr.22904
National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39(2(Suppl 1)):S1–S266
Levey AS, Eckardt KU, Tsukamoto Y et al (2005) Definition and classification of chronic kidney disease: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int 67:2089–2100. doi:10.1111/j.1523-1755.2005.00365.x
Torrisi R, Balduzzi A, Ghisini R, Rocca A, Bottiglieri L, Giovanardi F, Veronesi P, Luini A, Orlando L, Viale G, Goldhirsch A, Colleoni M (2007) Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel. Cancer Chemother Pharmacol Dec 7; [Epub ahead of print]
Coudert BP, Largillier R, Arnould L, Chollet P, Campone M, Coeffic D et al (2007) Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial. J Clin Oncol 25(19):2678–2684. doi:10.1200/JCO.2006.09.9994
Robert N, Leyland-Jones B, Asmar L, Belt R, Ilegbodu D, Loesch D et al (2006) Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 24(18):2786–2792. doi:10.1200/JCO.2005.04.1764
Hurley J, Doliny P, Reis I, Silva O, Gomez-Fernandez C, Velez P et al (2006) Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol 24(21):3515
Slamon D, Eiermann W, Robert N et al (2005) Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2-positive early breast cancer patients: BCIRG 006 study. 28th Annual San Antonio Breast Cancer Symposium. San Antonio abstract 1
Body JJ (2006) Breast cancer: bisphosphonate therapy for metastatic bone disease. Clin Cancer Res 12:6258s–6263s. doi:10.1158/1078-0432.CCR-06-0840
Tripathy AD, Diel I, Body JJ (2004) Ibandronate reduces skeletal morbidity in patients with breast cancer. Semin Oncol 31(5(Suppl 10)):64–66. doi:10.1053/j.seminoncol.2004.07.025
Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J et al (2003) Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 98(8):1735–1744. doi:10.1002/cncr.11701
Chang JT, Green L, Beitz J (2003) Renal failure with the use of zoledronic acid. N Engl J Med 349(17):1676–1679. doi:10.1056/NEJM200310233491721
Cockcroft DW, Gault MH (1976) Prediction of CrCl from serum creatinine. Nephron 16:31–41. doi:10.1159/000130554
Levey AS, Greene T, Kusek JW (2000) A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 11:0828 abstract
Aronoff GR, Berns JS, Brier ME et al (1999) Drug prescribing in renal failure. Dosing guidelines for adults, 4th edn. American College of Physicians-American Society of Internal Medicine, USA
Launay-Vacher V, Karie S, Deray G (2005) GPR Anticancéreux. Guide de prescription des médicaments chez le patient insuffisant rénal, 3rd edn. Méditions International, France
Lauro S, Lalle M, D’Andrea, Vecchione A, Frati L (1994) Nephrotic syndrome and adjuvant treatment with tamoxifen for early breast cancer. Case report and review of the literature. Anticancer Res 4(5B):171–172
Merouani A, Davidson SA, Schrier RW (1997) Increased nephrotoxicity of combination taxol and cisplatin chemotherapy in gynecologic cancers as compared to cisplatin alone. Am J Nephrol 17(1):53–58
Nikolsky E, Mehran R, Lasic Z et al (2005) Low hematocrit predicts contrast-induced nephropathy after percutaneous coronary interventions. Kidney Int 67:706–713. doi:10.1111/j.1523-1755.2005.67131.x
Body JJ, Coleman R, Clezardin P, Ripamonti C, Rizzoli R, Aapro M, International Society of Geriatric Oncology (2007) International Society of Geriatric Oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients. Eur J Cancer 43:852–858. doi:10.1016/j.ejca.2006.12.006
Lichtman S, Wildiers H, Launay-Vacher V, Steer C, Chatelut E, Aapro M (2007) International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer 43:14–34. doi:10.1016/j.ejca.2006.11.004
Launay-Vacher V, Chatelut E, Lichtman S, Wildiers H, Steer C, Aapro M (2007) Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology (SIOG) clinical practice recommendations. Ann Oncol 18:1314–1321. doi:10.1093/annonc/mdm011
Aapro M, Abrahamsson PA, Body JJ, Coleman RE, Colomer R, Costa L et al (2008) Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 19(3):420–432. doi:10.1093/annonc/mdm442
Body JJ, Diel IJ, Tripathy D, Bergstrom B (2006) Intravenous ibandronate does not affect time to renal function deterioration in patients with skeletal metastases from breast cancer: phase III trial results. Eur J Cancer Care (Engl) 15(3):299–302. doi:10.1111/j.1365-2354.2005.00641.x
Acknowledgements
Under the direction of the IRMA Scientific Committee, the IRMA Study has been coordinated by ICAR, a National Medical Advisory Service on the interactions between drugs and the kidney (i.e. drug dosage adjustment, drug nephrotoxicity, drug–drug interactions with immunosuppressive therapies) located in the Department of Nephrology at Pitié-Salpêtrière Hospital in Paris, France. The authors are indebted to the physicians who took time from their busy work schedules to participate in the IRMA Study Group and to Roche France, thanks to whom ICAR services are available to French oncologists through an unrestricted educational grant.
IRMA Scientific Committee (Alphabetical)
P. Beuzeboc, Paris; G. Deray, Paris; J. Gligorov, Paris; V. Launay-Vacher, Paris; J.-F. Morere, Paris; S. Oudard, Paris; X. Pourrat, Tours; I. Ray-Coquard, Lyon, J.-P. Spano, Paris.
IRMA Study Group (Alphabetical)
Pr A. Adenis, Lille; Dr E. Banu, Paris; Dr P. Beuzeboc, Paris; Dr H. Boostandoost, Paris; Dr S. Clisant, Lille; Dr N. Colbert, Paris; Dr L.-M. Dourthe, Metz; Dr D. Egret, Nantes; Dr J. Egreteau, Lorient; Dr J. Gligorov, Paris; Dr J.-P. Guastalla, Lyon; Dr M.-F. Jaeger, Metz; Dr F. Joly, Caen; Dr J. Ayllon, Paris; Dr C. Le Tourneau, Paris; Dr C.-B. Levache, Périgueux; Dr A. Lortholary, Nantes; Mr C. Maguire, Périgueux; Dr A. Monnier, Montbéliard; Pr J.-F. Morere, Paris; Dr E. Ouahrani, Paris; Pr S. Oudard, Paris; Dr I. Ray-Coquard, Lyon; Pr O. Rixe, Paris; Dr E. Sevin, Caen; Dr L. Stefani, Grenoble, France.
Author information
Authors and Affiliations
Consortia
Corresponding author
Rights and permissions
About this article
Cite this article
Launay-Vacher, V., Gligorov, J., Le Tourneau, C. et al. Prevalence of renal insufficiency in breast cancer patients and related pharmacological issues. Breast Cancer Res Treat 124, 745–753 (2010). https://doi.org/10.1007/s10549-008-0131-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-008-0131-1